Megalin antagonist
US10420741B2 · kind B2 · utility
0Cited by
0References
11Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 21, 2016 |
| Grant date | Sep 24, 2019 |
| Priority date | — |
| Expiry date | Jan 30, 2037 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention includes cilastatin or a pharmaceutically acceptable salt thereof as an active component and a suppressant for renal impairment or inner ear disorders, induced via megalin by at least one megalin ligand which is selected from the group consisting of polymyxins, aminoglycoside antibiotics, glycopeptide antibiotics, cisplatin, and pharmaceutically acceptable salts thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.